Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study

References

• United Nations Office on Drugs and Crime (UNODC) World Drug Report, 2012. United Nations Office on Drugs and Crime. Available at: http://unp.un.org
   Google Scholar
• Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of National Findings (Office of Applied Studies, NSDUH Series H-38A, HHS Publication No. SMA 10-4856 Findings). Rockville, MD; 2010
   Google Scholar
• European Monitoring Centre for Drug and Drug addiction (EMCDDA) Annual report on the state of the drugs problem in Europe EMCDDA, Lisbon, November 2012. Available at: http://www.emcdda.europa.eu
   Google Scholar
• Copeland J, Swift W, Roffman R, Stephens RS. A randomized controlled trial of brief cognitive – behavioral interventions for cannabis use disorder. J Subst Abuse Treat 2001;21:55–64
   PubMed Web of Science ®Google Scholar
• Stephens RS, Roffman RA, Simpson EE. Treating adult marijuana dependence: a test of the relapse prevention model. J Consult Clin Psychol 1994;62:92–99
   PubMed Web of Science ®Google Scholar
• Stephens RS, Roffman RA, Curtin L. Extended versus brief treatment for marijuana use. J Consult Clin Psychol 2000;68:898–908
   PubMed Web of Science ®Google Scholar
• Moore BA, Budney AJ. Relapse in outpatient treatment for marijuana dependence. J Sub Abuse Treat 2003;25:85--89
   Google Scholar
• Budney AJ, Radonovich KJ, Higgins ST, Wong CJ. Adults seeking treatment for marijuana dependence: a comparison with cocaine-dependent treatment seekers. Exp Clin Psychopharmacol 1998;6:419–426
   PubMed Web of Science ®Google Scholar
• Budney AJ, Hughes JR, Moore BA, Novy PL. Marijuana abstinence effects in mariujana smokers maintained in the home environment. Arch Gen Psychiat 2001;58:917–924
   PubMed Web of Science ®Google Scholar
• Budney AJ, Moore BA, Vandrey RA, Hughes JR. Onset, magnitude, and duration of abstinence effects following heavy marijuana use. Drug Alcohol Depend 2002;66:S23
   Google Scholar
• Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiat 2004;161:1967–1977
   PubMed Web of Science ®Google Scholar
• Kouri EM, Pope HG. Abstinence symptoms during withdrawal from chronic marijuana use. Exp Clin Psychopharmacol 2000;8:483–492
   PubMed Web of Science ®Google Scholar
• Budney AJ, Hughes JR. The cannabis withdrawal syndrome. Curr Opin Psychiat 2006;19:233–238
   PubMed Web of Science ®Google Scholar
• Petronis KR, Samuels JF, Moscicki EK, Anthony JC. An epidemiologic investigation of potential risk factors for suicide attempts. Soc Psychiat Psychiat Epidemiol 1990;25:193–199
   PubMed Web of Science ®Google Scholar
• Rowe MG, Fleming MF, Barry KL, Manwell LB, Kropp S. Correlates of depression in primary care. J Family Prac 1995;41:551–558
   PubMed Web of Science ®Google Scholar
• Deykin EY, Levy JC, Wells V. Adolescent depression, alcohol and drug abuse. Am J Public Health 1986;76:178–182
   PubMedGoogle Scholar
• Gruber AJ, Pope HG, Brown ME. Do patients use marijuana as an antidepressant? Depression 1996;4:77–80
   PubMedGoogle Scholar
• Arendt M, Rosenberg R, Fjordback L, Brandholdt J, Foldager L, Sher L, Munk-Jørgensen P. Testing the self-medication hypothesis of depression and aggression in cannabis-dependent subjects. Psychol Med 2007;37:935–945
   PubMed Web of Science ®Google Scholar
• Hasin DS, Keyes KM, Alderson D, Wang S, Aharonovich E, Grant BF. Cannabis withdrawal in the United States: results from NESARC. J Clin Psychiatry 2008;69:1354–1363
   PubMed Web of Science ®Google Scholar
• Levin KH, Copersino ML, Heishman SJ, Liuc F, Kelly DL, Boggs DL, Gorelick DA. Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. Drug Alcohol Depend 2010;111:120–127
   PubMed Web of Science ®Google Scholar
• Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, Buffkins K, et al. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology 2012;37:1689–1698
   PubMed Web of Science ®Google Scholar
• Gray KM, Watson NL, Carpenter MJ, LaRowe SD. N-Acetylcysteine (NAC) in young marijuana users: an open-label pilot study. Am J Addict 2010;19:187–189
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JPT, Churchill R, Watanabe N, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. The Lancet 2009;373:746–758
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994
   Google Scholar
• Beck AT. Depression inventory. Philadelphia: Center for Cognitive Therapy; 1978
   Google Scholar
• Spielberger CD, Gorsuch RL, Lushene RE. Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press; 1970
   Google Scholar
• McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argerio M. The fifth edition of the Addiction Severity Index. J Sub Abuse Treat 1992;9:199--213
   Google Scholar
• Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar). Br J Addict 1989;84:1353–1357
   PubMedGoogle Scholar
• Milin R, Manion I, Dare G, Walker S. Prospective assessment of cannabis withdrawal in adolescents with cannabis dependence: a pilot study. J Am Acad Child Adol Psychiat 2008;47:174–178
   PubMed Web of Science ®Google Scholar
• Budney A, Higgins ST, Radonovich KJ, Novy PL. Adding voucher-based incentives to coping skills and motivational enhancement improves outcome during treatment for marijuana dependence. J Consulting Clin Psychol 2000;68:1051–1061
   PubMed Web of Science ®Google Scholar
• Marlatt GA, Gordon JR. Relapse prevention. New York, USA: Guilford Press; 1985
   Google Scholar
• Miller WR, Rollnick S. Motivational interviewing: preparing people to change addictive behavior. New York: Guilford Press; 1991
   Google Scholar
• Fisher LD, Dixon DO, Herson J, Frankowski RK, Hearron MS, Peace KE. Intention to treat in clinical trials. In: Peace KE, ed. Statistical issues in drug research and development. New York: Marcel Dekker; 1990:331–350
   Google Scholar
• Hart CL. Increasing treatment options for cannabis dependence: a review of potential pharmacotherapies. Drug Alcohol Depend 2005;80:147–159
   PubMed Web of Science ®Google Scholar
• Vandrey R, Haney M. Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs 2009;23:543–553
   PubMed Web of Science ®Google Scholar
• Haney M, Ward AS, Comer SD, Hart CL, Foltin RW, Fischman MW. Bupropion SR worsens mood during marijuana withdrawal in humans. Psychopharmacology 2001;155:171--179
   Google Scholar
• Haney M, Hart CL, Ward AS, Foltin RW. Nefazodone decreased anxiety during marijuana withdrawal in humans. Psychopharmacology (Berl) 2003;165:157–165
   PubMed Web of Science ®Google Scholar
• Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubaran C, Foltin RW. Marijuana withdrawal in humans: effects of oral THC or divalproex. Neuropsychopharmacology 2004;29:158–170
   PubMed Web of Science ®Google Scholar
• Levin FR, McDowell D, Evans SM, Nunes E, Akerele E, Donovan S, Vosburg SK. Pharmacotherapy for marijuana dependence: a double-blind, placebo-controlled pilot study of divalproex sodium. Am J Addict 2004;13:21–32
   PubMed Web of Science ®Google Scholar
• Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Foltin RW. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology 2008;197:157–168
   PubMed Web of Science ®Google Scholar
• Carpenter KM, McDowell D, Brooks DJ, Cheng WY, Levin FR. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am J Addict 2009;18:53–64
   PubMed Web of Science ®Google Scholar
• Haney M, Hart CL, Vosburg SK, Comer SD, Collins S, Reed SC, Cooper Z, Foltin RW. Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology 2010;211:233–244
   PubMed Web of Science ®Google Scholar
• Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 2007;86:22–29
   PubMed Web of Science ®Google Scholar
• Vandrey R, Smith MT, McCann UD, Budney AJ, Curran EM. Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal. Drug Alcohol Depend 2011;117:38–44
   PubMed Web of Science ®Google Scholar
• Cornelius JR, Clark DB, Bukstein OG, Bimaher B, Salloum IM, Brown SA. Acute phase and five year follow-up atusy of fluoxetine in adolescents with major depression and comorbid substance abuse disorder: a review. Addict Behav 2005;30:1824–1833
   PubMedGoogle Scholar
• McRae AL, Brady KT, Carter RE. Buspirone for treatment of marijuana dependence: a pilot study. Am J Addict 2006;15:404
   PubMed Web of Science ®Google Scholar
• McRae-Clark AL, Carter RE, Killeen TK, Carpenter MJ, Wahlquist AE, Simpson SA, Brady KT. A placebo-controlled trial of buspirone for the treatment of marijuana dependence. Drug Alcohol Depend 2009;10:132–138
   Google Scholar
• Nordstrom BR, Levin FR. Treatment of cannabis use disorders: a review of the literature. Am J Addict 2007;16:331–342
   PubMed Web of Science ®Google Scholar
• Weinstein AM, Gorelick DA. Pharmacological treatment for cannabis dependence. Curr Pharma Design 2011;17:1351–1358
   PubMed Web of Science ®Google Scholar
• Cornelius JR, Buksteinb OG, Douaihy AB, Clark DB, Chung TA, Daley DC, Wood DS, Brown SJ. Double-blind fluoxetine trial in comorbid MDD–CUD youth and young adults. Drug Alcohol Depend 2010;112:39–45
   PubMedGoogle Scholar